Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Roche will license, develop, and market Ipsen's antidiabetes drug BIM 51077, a glucagon-like peptide 1 (GLP-1) analog. Roche decided to exercise its option under a 2003 agreement following favorable Phase I and II clinical trials. Roche will pay Ipsen $71 million up front and an additional $3.8 million after closing of Ipsen's 2006 financial statements. Additional milestone payments to Ipsen could total $214 million.
This article has been sent to the following recipient: